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Background: Surgical site infections (SSIs) are the most costly and second most
frequent healthcare-associated infections in the Western world. They are responsible
for higher postoperative mortality and morbidity rates and longer hospital stays. The aim
of this study is to analyze which factors are associated with SSI in a modern general
thoracic practice.
Methods: Data were collected from our department’s quality database. Consecutive
patients operated between January 2014 and December 2018 were included in this
retrospective study.
Results: A total of 2430 procedures were included. SSIs were reported in 37 cases
(1.5%). The majority of operations were video-assisted (64.6%). We observed a shift
toward video-assisted thoracic surgery in the subgroup of anatomical resections during
the study period (2014: 26.7%, 2018: 69.3%). The multivariate regression analysis
showed that blood loss >100ml (p = 0.029, HR 2.70) and open surgery (p = 0.032, HR
2.37) are independent risk factors for SSI. The latter was higher in open surgery than in
video-assisted thoracic procedures (p< 0.001). In the subgroup of anatomical resection,
we found the same correlation (p = 0.043). SSIs are also associated with significantly
longer mean hospital stays (17.7 vs. 7.8 days, p < 0.001).
Conclusion: As SSIs represent higher postoperative morbidity and costs, efforts should
be made to maintain their rate as low as possible. In terms of prevention of SSIs,
video-assisted thoracic surgery should be favored over open surgery whenever possible.
Keywords: surgical site infection, minimal invasive surgery, video-assisted thoracic surgery, thoracic surgery,
complication
INTRODUCTION
Surgical site infections (SSIs) are the second most frequent healthcare-associated infections in
the United States and Europe (1). The overall incidence of SSI in general surgery was reported
to be between 1.9 and 5.4% (2–4). Higher SSI rates can be found after colectomies (18.4%) (5).
In thoracic surgery, there are some studies reporting SSI occurrence ranging from 0.3 to 6.1%,
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but no study looks specifically for factors associated with this
burden in a recent period and in a fully implemented minimal
invasive practice (6–11).
In the United States, SSIs represent themost costly healthcare-
associated infection. They cause higher postoperative mortality,
morbidity, and longer hospital stays (12). It is estimated that
55% of SSIs are preventable with the implementation of official
recommendations (13, 14).
SSIs are defined by the United States Centers for Disease
Control and Prevention (CDC) as “an infection that occurs after
surgery in the part of the body where the surgery took place”
(15). Superficial SSIs involve only the skin and subcutaneous
tissue while deep SSIs affect tissues under the skin like muscle,
fascia, adjacent organs/space opened, or manipulated during the
operation or foreign body (15–18).
Many risk factors for SSI have been identified in general
surgery, such as advanced age, previous radiation, previous
skin and soft-tissue infection, high level of serum glucose,
obesity, smoking, immunosuppression, malnutrition, malignant
disease, hospitalization during the preoperative period, ongoing
infection, blood transfusion, and longer operating time (13).
After a progressive introduction during the last three decades,
video-assisted thoracic surgery (VATS) is commonly used.
VATS in simple thoracic procedures such as pleural biopsy or
pleurodesis is relatively easy to perform. VATS in more complex
procedures such as lobectomy or segmentectomy can be a real
challenge due to a longer learning curve. This results in longer
operating times and higher intraoperative complication rates
during that learning period (6). Its use in oncological procedures
was a controversial subject until proven otherwise (8, 19–22).
With experience, operation durations tend to be lower with less
intraoperative complications (8, 19, 20). Recent studies report
fewer postoperative complications, shorter hospital stay, and
shorter chest tube duration without compromising oncological
outcomes in VATS (8, 19, 23). Only two studies specifically
analyze the risk factors for SSI in thoracic surgery in relation to
open or minimally invasive surgery (10, 24). However, they are
not able to demonstrate open surgery as a risk factor for SSI in
comparison with minimal invasive surgery and they cover a long
period of time before the implementation of VATS surgery for
anatomical lung resections. Since VATS is now a well-established
technique and is regularly performed with the development of
expertise, we believe its positive influence on SSI rates in thoracic
surgery can be better recognized.
Our study aims to assess the SSI rate over a 5-year period in a
general thoracic “real-life” practice and to determine associated
risk factors for SSI. During the same period, we implemented
our VATS program for anatomical lung resection giving the
possibility to measure its effect on this particular complication.
MATERIALS AND METHODS
Patient Inclusion Criteria
Data were collected from the department quality database,
which uses the tool of the Association for Quality Assurance in
Surgery (AQC). Data are routinely entered prospectively into
the database by a trained study nurse. Consecutive patients
who underwent a thoracic operation between January 2014 and
December 2018 at the Department of Thoracic Surgery of our
university tertiary reference center were included. Tracheostomy,
bronchoscopy, operation for vascular access, debridement of SSI,
or reoperation for post-operative complication within 30 days
after thoracic surgery was excluded. Patients <18 years of age
were also excluded. This study was approved by the local ethic
committee (Project-ID 2020-00850); each patient gave written
consent for the use of his/hermedical data during hospitalization.
Patient Characteristics
The following clinicopathological variables were recorded: age,
sex, BMI, ASA score, comorbidity, previous chemotherapy, or
radiotherapy and chronic steroid use.
Patients’ demographics includes also the following criteria:
malignant and benign pathology of the main bronchus/trachea,
of the mediastinum, primary lung malignancy, malignant
pathology of the pleura, other malignant pathology,
empyema, pneumothorax, pleural effusion and hemothorax,
musculoskeletal pathology (unstable rib fracture, pectus
excavatum/carinatum), complication after medical treatment or
extra-thoracic surgery, and other benign pathology.
Subgroups were made according to operation type: simple
thoracoscopy (biopsy, wedge resection, and pleurodesis),
decortication and pleurectomy, lobectomy, segmentectomy,
pneumonectomy, thymectomy, sympathectomy, mediastinum
operation, and other.
For each operation, access type (open, VATS, and conversion)
was specified, and whether it was elective or not. Operating
time was reported in minutes, and estimated blood loss was
reported in milliliters. A cutoff for blood loss was made at 100ml,
as literature reports higher cardiopulmonary complications in
VATS surgery with blood loss above 100 ml (25).
Intraoperative complications were reported in four
subgroups: vascular lesion, other organ lesions, operation
interruption, and other intraoperative complications.
Postoperative complications after the surgical procedure were
classified according to the Clavien–Dindo classification (26).
Clavien–Dindo grade≥3b was considered a severe postoperative
complication. Postoperative complications were divided into
the following subgroups: respiratory complication (pneumonia,
atelectasis, respiratory insufficiency, pneumothorax, and
persistent air leakage, i.e.,>5 days), cardiovascular complication,
SSI, postoperative bleeding, and persistence of chest tube
secretion (>200 ml/24 h for >7 days), bronchial stump
insufficiency, hemothorax, chylothorax, empyema, and other
complications. More than one complication can be reported
per operation. Pneumonia, empyema, and bronchial stump
insufficiency were not included in SSI but reported separately.
SSI Definition
SSI was defined according to the abovementioned CDC
definition (16). An SSI was diagnosed with the presence
of redness, tenderness, heat, localized swelling, fever,
purulent discharge, spontaneous wound dehiscence, and/or
microorganism isolated form the wound fluid or tissue. The SSI
was diagnosed through the attending surgeon.
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Surgical Procedure
In our clinic, VATS is performed using a two- or three-
port access. For anatomical lung resections, we modified
our approach to a uniportal VATS technique, consisting of
a 3- to 5-cm incision length, in November 2014. No rib
spreader was used for multiport VATS and soft wound
protectors were used in uniportal VATS. Standard patient
preparation for surgery includes disinfection with povidone-
iodine solution (Betaseptic R©). Prophylactic antibiotics were
routinely administrated 30–45min prior to skin incision with
cefuroxime 1.5 g as standard dosage (or Clindamycin in case
of β-lactam allergy). If an antibiotic treatment was already
initiated, it was repeated prior to the incision in place of
the standard prophylaxis. Antibiotics were adapted to the
clinical situation, like the use of broader spectrum in case
of empyema for example. For low infection risk surgery
such as simple biopsy, the surgeon remains autonomous to
decide whether a prophylaxis is needed or not. The skin
was closed by means of a continuous intracutaneous suture
with Monocryl R©4–0.
During hospital stay, each patient was monitored for peri-
and postoperative complications including SSI. A clinical nurse
contacted each patient 7–10 days after hospital discharge by
telephone to inquire about his/her general well-being and
presence of any wound infection or discharge. Routine outpatient
visits were performed 2–4 weeks after surgery.
Endpoints
The endpoint of our study was to determine the risk factors
associated with SSI. Since we initiated our uniportal VATS
program during the study period, we also analyzed what effect the
minimal invasive approach had on SSI, especially in anatomical
lung resections.
Statistical Analysis
Baseline characteristics are presented as medians (IQR)
for continuous variables or frequencies for categorical
variables. Aiming to identify factors associated with SSI,
the following clinicopathological variables were analyzed using a
univariate logistic regression model: previous chemotherapy or
radiotherapy, chronic use of a corticosteroid, diabetes mellitus,
comorbidity, ASA status, blood loss, access type, BMI, and
log-transformed operation time in order to have it normally
distributed. The maximal number of variable included in
the multivariate analysis will be determined according to the
incidence of SSI rate (according to the “one in ten rule”). In the
subsequent multivariate analysis, the factors with significant
p-value in univariate analysis were entered in a logistic regression
model to identify predictors for SSI. Fisher’s exact test was used to
compare the overall number of SSIs by type of operation. Mann–
Whitney U test and Kruskal–Wallis test were used to compare
continuous variables and Fisher’s exact test for categorical
variables for comparing VATS vs. conversion vs. open surgery
group. p-values < 0.05 were considered statistically significant.
Analyses were done using Stata 15 (Stata, RRID:SCR_012763).
TABLE 1 | Clinicopathological characteristics of 2,430 patients undergoing a
thoracic surgery.
Variable All n (%) or
median (IQR)
N = 2,430
Age 62.0 (49.0; 71.0)
Female 847 (34.9)






Cardiovascular disease 462 (19.0)
Pulmonary disease 610 (25.1)
Neurological/psychiatric disease 189 (7.8)
Kidney disease 197 (8.1)
Liver disease 68 (2.8)
Diabetes mellitus 227 (9.3)
Oncological disease 1,170 (48.1)
No comorbidity 688 (28.3)
Previous chemotherapy 254 (10.5)
Previous radiotherapy 128 (5.3)
Chronic steroid use 65 (2.7)
Main diagnosis
Main bronchus, trachea pathology (malignant/benign) 7 (0.3)/1 (0.04)
Primary lung malignancy (NSCLC) 690 (28.4)
Mediastinum pathology (malignant/benign) 31 (1.3)/56 (2.3)
Malignant pleural pathology (mesothelioma) 104 (4.4)
Malignant pathology other 329 (13.5)
Benign pathology other 493 (20.3)
Empyema 208 (8.6)
Pneumothorax 147 (6.0)
Pleural effusion/hemothorax 83 (3.4)/31 (1.3)
Operation on the musculoskeletal apparatus 188 (7.7)
Postoperative complication 62 (2.6)




For the reviewed period, 2,671 patients were operated at our
department. Due to the abovementioned exclusion criteria, 241
procedures were excluded, leaving 2,430 patients/operations
fulfilling the inclusion criteria (2014: 431 patients, 2015:
454, 2016: 476, 2017: 509, 2018: 560). Clinicopathological
characteristics are summarized in Table 1.
Perioperative Outcome
Elective surgery was mainly performed (93.4%). Antibiotics were
administrated prior to the incision or were already prescribed
as a therapy in 97.1% of the cases. The median operation
time was 85min. In 24.2% of operations, blood loss was
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TABLE 2 | Perioperative characteristics of 2,430 patients undergoing a thoracic
surgery.



















Prophylaxis prior to incision or therapeutic 2,359 (97.1)
Prophylaxis after incision 28 (1.2)
No antibiotics 37 (1.5)
Unknown 6 (0.2)
Elective operation 2,269 (93.4)
Operation time (min) 85.0 (50.0; 138.0)
Blood loss >100ml 589 (24.2)
Hospitalization duration (days) 6.0 (4.0; 9.0)
Intraoperative complications 104 (4.3)
Vascular lesion 18 (0.7)
Lesion of other organ 6 (0.2)
Operation Interruption 6 (0.2)
Other 76 (3.1)
Postoperative complications (all Clavien–Dindo Grad) 954 (39.3)
Respiratory complication 121 (5.0)
Pneumothorax, persistent air leak 98 (4.0)
Cardiovascular complication 59 (2.4)
Surgical site infection 37 (1.5)
Bleeding 33 (1.4)
Decubitus 16 (0.7)
Persistence of drain secretion 10 (0.4)
Bronchial stump insufficiency 9 (0.4)
Hemothorax/chylothorax/empyema 5 (0.2)/6 (0.2)/8 (0.3)
Other 857 (35.2)
Clavien–Dindo classification ≥3b 108 (4.4)
Postoperative mortality (Grad 5) 17 (0.7)
>100ml. Median hospitalization time was 6 days. For 104 (4.3%)
operations, an intraoperative complication was reported. The
global postoperative complication rate was 39.3% (n = 954), and
there were 4.4% (n = 108) complications with a Clavien–Dindo
grade ≥3b. Postoperative mortality was 0.7% (Table 2).
TABLE 3 | Analysis of factors associated with surgical site infection in 2,430
patients undergoing thoracic surgery.
Variable UV MV







Diabetes mellitus 1.53 (0.59–3.96) 0.384
Comorbidity 2.06 (0.86–4.96) 0.101
ASA score ≥3 2.30 (1.01–5.26) 0.048 1.54 (0.65–3.66) 0.328
Blood loss
>100ml
4.21 (2.11–8.40) <0.001 2.70 (1.11–6.55) 0.029
VATS Ref. Ref.
Open 4.17 (2.10–8.28) <0.001 2.37 (1.08–5.24) 0.032
Conversion 2.44 (0.31–19.05) 0.394
BMI 1.00 (0.93–1.07) 0.985
OP Time (min) 1.82 (1.10–3.01) 0.02 0.99 (0.53–1.82) 0.968
ASA, american society of anesthesiologists; BMI, body mass index; CI, confidence
interval; MV, multivariate logistic regression analysis; HR, Hazard ratio; UV, univariate
logistic regression analysis; VATS, video-assisted thoracic surgery.
SSI
SSIs were reported in 37 cases (1.5%). For the logistic regression
analysis, patients with unknown access type were excluded (128
patients). Univariate logistic regression analysis showed that ASA
score≥3, blood loss>100ml, open surgery, and longer operation
time were associated with higher SSI rate. For the access type,
the open subgroup and the conversion subgroup were compared
individually to the VATS subgroup. In the multivariate logistic
regression analysis, blood loss >100ml [p = 0.029, HR 2.70
CI (1.11–6.55)] and open surgery [p = 0.032, HR 2.37 CI
(1.08–5.24)] were independent risk factors for SSI (Table 3).
Conversion was not a risk factor for SSI. The only SSI occurring
after a conversion was in a patient with severe comorbidities
operated for an empyema.
The difference in SSI rate between open procedure and VATS
was statistically significant [3.4 vs. 0.8% (p < 0.001)]. The
difference was also significant in the anatomical resection group
[2.3 vs. 0.2% (p= 0.043)] (Figure 1).
In the empyema subgroup (208 cases), the majority of cases
were operated with a minimal invasive technique [VATS = 141
(67.8%) including 12 conversions vs. open = 59 (28.4%) and 8
missing data (3.8%)]. In this subgroup, 10 (4.8%) SSIs occurred
(VATS= 3, open= 6, missing= 1).
SSIs were associated with longer hospital stays for all
operations (6 vs. 14 days, p < 0.001) and for anatomical
resections (7 vs. 17 days, p < 0.001) (Table 4). When SSIs were
diagnosed, the mean hospital stay was 9.9 days longer for all
thoracic operations and 14.5 days longer in anatomical resection.
Persistent air leak was present in one patient with SSI, and even
after exclusion of this patient, the length of stay was longer
in the SSI subgroup (median 13.5 days). In the anatomical
resection subgroup, the Number Needed to Treat using the VATS
technique to prevent one SSI was 47.6.
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FIGURE 1 | Comparison of surgical site infection (n) for (A) 2,430 patients
undergoing thoracic surgery and (B) 700 patients undergoing anatomical
resection according to access type.
Open vs. VATS
Themajority of operations were performed using a video-assisted
approach (64.6%) with a conversion rate of 3.1% (50/1619). The
proportion of VATS increased over the years, from 51.5% (n =
222) in 2014 to 67% (n = 375) in 2018. This is mainly due to
the implementation of our VATS program for anatomical lung
resections. The rate of conversions ranged from 1.8% (6/336) to
6.0% (20/335), with the highest rate in 2015 and the lowest rate
in 2016 and 2018 (Figure 2A).
In the cohort undergoing an anatomical lung resection, 58.6%
(n = 410) of procedures were done by VATS. In this subgroup,
VATS surgery strongly increased over the years [26.7% (n = 24)
to 69.3% (n = 115)] as it was progressively introduced at our
department as a standard procedure. During the first 2 years
(2014 and 2015), the conversion rate was higher [17.2% (5/29)
and 10.8% (7/65), respectively], reflecting the learning curve in
TABLE 4 | Comparison of hospitalization duration for 2,430 patients undergoing
thoracic operation and for 700 patients undergoing anatomical resection
according to SSI.




Without SSI 2,201 6 (4.0; 9.0)/7.8 <0.001
With SSI 37 14 (8.5; 21.0)/17.7
Missing data 192
Anatomical resection N = 700
Without SSI 693 7 (5.0; 9.5)/8.21 <0.001
With SSI 7 17 (16.0; 37.0)/22.71
IQR, interquartile range; SSI, surgical site infection.
**Mann–Whitney U test.
VATS anatomic resections (2016: 0%; 2017: 4.2%; 2018: 2.5%)
(Figure 2B).
Table 5 shows the comparison of clinicopathological data
between VATS (conversion included) and the open thoracic
surgery group. Except for previous chemotherapy and operation
indication, there was no statistical difference. However, the
outcome differs with a lower intraoperative (p < 0.001) and
postoperative morbidity (p < 0.001). Blood loss and operation
time were also lower in the VATS group.
DISCUSSION
Our study describes the SSI rate at our thoracic surgical
department between 2014 and 2018. Open surgery and blood loss
>100ml were found to be independent risk factors for SSI in the
multivariate analysis.
The overall SSI rate was 1.5%, which reflects current literature
rates mentioned above (6–11). There is no consensus on criteria
for the diagnosis of SSI (1, 4, 18). Up to 41 SSI definitions are
reported in the literature. Only five were reported as standardized
definitions: CDC-1988, CDC-1992, SISG (Surgical Infection
Study Group), NPS (National Prevalence Survey), and PHLS
(Public Health Laboratory Service) (1, 17, 27). This variety of SSI
definitions can result in over-/underreporting of SSI rates (27).
We did not consider empyema and pneumonia as SSI, since
both can be present in other situations (e.g., in case of bronchial
stump insufficiency or atelectasis). Most studies reporting SSI in
thoracic surgery did the same. As an exception, the second study
of Imperatori et al. on the subject in 2017 includes pneumonia
and empyema in SSI. This was not the case in their previous study
in 2006 (9, 24).
CurrentWHO recommendations for the prevention of SSI are
reported in “Global Guidelines for the Prevention of Surgical Site
Infection” (1). Except for antimicrobial-coated sutures, our clinic
puts effort into following the current recommendations for the
prevention of SSI in a standardized way. Our strong adherence
to current WHO recommendations probably played a role in the
low SSI rate reported in our study.
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FIGURE 2 | Access type (%) for (A) 2,430 patients undergoing thoracic surgery and (B) 700 patients undergoing anatomical resection.
We observed a good adherence to protocols for the
administration of antibiotic prophylaxis (or the ongoing
antibiotic treatment) in 97.1% of the cases. Antibiotic given after
the incision (1.2%) can occur when collection of samples for
microbial determination is required prior to the administration
of antibiotics.
In colorectal surgery, the superiority of laparoscopic surgery
has been demonstrated as well as its association with lower SSI
rates (28). There are little data determining the influence of VATS
on SSI rate especially for anatomical lung resection. Imperatori
et al. reported a SSI incidence of 3.2% in 988 thoracic surgical
procedures during the years 1996–2005. SSI rate was lower in
wedge resections by VATS than in open surgery (5.5 vs. 17.9%,
p < 0.001), but all anatomical resections were performed by
an open approach (9). In his second study from 2006 to 2015,
the multivariate analysis did not identify open surgery as a risk
factor for SSI in comparison with VATS (24). Only 36 of the
512 anatomical resections were performedwith VATS. Cvijanović
et al. reported a SSI rate of 6.1% in thoracic surgery in 3,370
patients over a 12-year period (VATS: 2.14%, Open 7.1%), but
the result was not significant in a multivariate analysis aiming
to identify SSI risk factor and only 30 of the 1,319 anatomical
resections were performed by VATS (10). In all these studies, the
compared groups were rather heterogeneous, and although the
study of Cvijanović et al. is one of the largest studies investigating
this matter in thoracic surgery so far, the long study period
includes a lot of changes in patient treatment (used disinfectant,
preoperative antibiotics, surgical technique, etc.). Three studies
based on large state or society databases mention SSI rate but
not as one of their main endpoints. Falcoz et al. reported a
significantly lower SSI rate in VATS lobectomy (0.2%) vs. open
(0.7%, p = 0.0218) for primary non-small cell lung cancer in
a propensity-matched analysis (21). Two other studies did not
confirm the advantage of VATS lobectomy concerning the SSI
rate (6, 23).
High blood loss is often a marker of longer and more difficult
operations with probable need for transfusion and is associated
with more complications, especially of cardiopulmonary origin,
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TABLE 5 | Comparison of clinicopathological characteristics of 700 patients undergoing anatomical resection (VATS = 410, Open = 257, Conversion = 20, Missing
data = 13) according to access type.
Variable VATS
n (%) or median (IQR)
N = 410
Conversion
n (%) or median (IQR)
N = 20
Open surgery
n (%) or median (IQR)
N = 257
p-value*
Age 66 (59.0; 72.0) 64.5 (58.0; 69.75) 64 (57.0; 71.0) 0.063
Men 264 (64.4) 13 (65) 160 (62.3) 0.568
BMI 24.5 (21.70; 28.15) 24.2 (22.03; 28.2) 24.8 (21.9; 28.4) 0.551
ASA score ≥3 321 (78.3) 17 (85%) 212 (82.5) 0.237
Comorbidity
Cardiovascular disease 104 (25.4) 4 (20%) 62 (24.1) 0.785
Pulmonary disease 138 (33.7) 6 (30) 95 (37.0) 0.364
Neuro/psych. disease 29 (7.1) 2 (10) 27 (10.5) 0.156
Kidney disease 34 (8.3) 0 (0) 18 (7.0) 0.766
Liver disease 14 (3.4) 0 (0) 7 (2.7) 0.821
Diabetes mellitus 35 (8.5) 1 (5) 29 (11.3) 0.226
Oncological disease 310 (75.6) 17 (85) 202 (78.6) 0.344
No comorbidity 34 (8.3) 1 (5) 20 (7.8) 0.886
Previous chemotherapy 41 (10.0) 3 (15) 51 (19.8) 0.001
Previous radiotherapy 31 (7.5) 3 (15) 21 (8.2) 0.886
Chronic steroid use 7 (1.7) 0 (0) 9 (3.5) 0.124
Operation indication 0.001
Oncological 348 (84.9) 20 (100) 238 (92.6)
Benign 54 (13.2) 0 (0) 12 (4.7)
Infectious 8 (2.0) 0 (0) 7 (2.7)
Elective operation 409 (99.8) 20 (100) 253 (98.4) 0.068
Operation time (min) 122 (98.0; 152.0) 180 (139.5; 218.75) 174 (136.25; 224.75) <0.001
Blood loss >100ml 110 (26.8) 12 (60) 168 (65.4) <0.001
Hospitalization duration (days) 6 (5.00; 8.00) 8 (6.25; 13.75) 9 (8.00; 12.00) <0.001
Clavien–Dindo ≥3b 20 (4.9) 2 (10) 30 (11.7) 0.003
Postoperative mortality 1 (0.2) 0 (0) 4 (1.6) 0.068
Intraoperative complications 7 (1.7) 7 (35) 25 (9.7) 0.001
Postoperative complications 182 (44.4) 9 (45) 170 (66.1) <0.001
Surgical site infection 1 (0.2) 0 (0) 6 (2.3) 0.013
ASA, American society of anesthesiologists; BMI, body mass index; IQR, interquartile range VATS, video-assisted thoracic surgery.
*Fisher’s exact test for categorical variables, Kruskal–Wallis test for continuous variables.
as well as shorter survival and immunity impairment (19, 25).
Mean blood loss is reported to be lower in VATS surgery
and could therefore indirectly influence the SSI rate in VATS
operations (13, 19, 22). In our study, however, a blood
loss >100ml was an independent risk factor for SSI in the
multivariate analysis.
In current literature, intraoperative complications tend to
be identical or higher in VATS than in open surgery (6, 23).
The length of hospital stay, overall hospitalization costs, and
postoperative complication seem similar or even better for
VATS (6, 8, 20). The implementation of the VATS program
at our department in the initial study period showed typical
characteristics of the learning curve with a conversion rate
falling from 4.4% to 1.3–1.6%. Intraoperative and postoperative
complications were lower in VATS along the whole period.
Cvijanovic et al. as well as our study showed that conversion is
not associated with a higher SSI rate (p = 0.733) (10). It seems
therefore reasonable to attempt a minimally invasive operation
even when the risk of conversion is high.
As SSIs represent longer hospital stay, rehospitalization,
reoperation, and specific care, it is associated with higher costs.
Cost burden associated with SSI in Europe is estimated at
1.47–19.1 billion Euro with 7–14 days of extended hospital
stay (4, 29). Our study reports a longer hospital stay in the
SSI subgroup. However, other postoperative complications were
also more frequent in this subgroup. Therefore, the extended
hospitalization can also be explained with a complication cascade
including SSI and not solely resulting from an SSI occurrence.
Our study presents the limitation of being retrospective, and
the comparison of VATS and open surgery groups for anatomical
resection has an inherent bias. There were more preoperative
chemotherapies (10.2 vs. 19%) and indication for operation was
more often oncological in the open group (92.6 vs. 84.9%).
Patient requiring neoadjuvant chemotherapy often have larger
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tumors and positive mediastinal lymph nodes and, consequently,
open surgery was preferred, especially during the learning phase.
However, it is important to notice that the rate of patients
operated for infectious diseases (suspicion of malignancy for
nodules of organizing pneumonitis) were similar in the open and
VATS subgroups (2.7% resp. 2.0%). Interestingly, the 20 cases
necessitating a conversion had no SSI. During the learning phase,
complex anatomical resection was performedwith an open access
and could be responsible for a higher rate of intraoperative
complications and blood loss. However, this can also be the case
for the VATS subgroup where operations performed during the
learning phase were included.
We deliberately included cases of empyema in our study for
a real-life global overview on the causes of SSI. The majority of
those cases were operated with a minimally invasive technique
and cannot be an explanation for the global lower SSI rate in
the VATS subgroup. Nevertheless, our study is one of the largest
study to investigate the matter of SSI in general thoracic surgery
practice and especially includes the most homogeneous patients
and standardized procedures so far.
CONCLUSION
SSI is associated with open approach and higher blood loss in
a general thoracic surgery practice. They are also correlated to
higher postoperative morbidity and longer hospital stay, leading
to higher overall costs, and attempts should be made to prevent
them. From the two risk factors identified, only the minimal
invasive approach can be influenced by the surgeon, and since
conversion does not seem to harm the patient, we advocate a
primary VATS approach whenever possible.
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